Full text
Earnings transcript
Read the complete earnings call transcript.
BSX
Boston Scientific Corporation
$62.82
0.82
(1.32%)
[ms_data_label text=’Delayed data’]
| Exchange: | NYSE |
| Market Cap: | 93.218B |
| Shares Outstanding: | 380M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Michael F. Mahoney | |||||
| Full Time Employees: | 53000 | |||||
| Address: |
| |||||
| Website: | https://www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 14,240,000 | 16,747,000 | 20,074,000 |
| Gross Profit | 8,831,000 | 10,267,000 | 13,853,000 |
| EBITDA | 3,453,000 | 3,938,000 | 3,733,000 |
| Operating Income | 2,181,000 | 2,635,000 | 3,971,000 |
| Net Income | 1,593,000 | 1,854,000 | 2,886,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 35,136,000 | 39,395,000 | 43,673,000 |
| Total Liabilities | 15,606,000 | 17,392,000 | 19,201,000 |
| Total Stockholders Equity | 19,282,000 | 21,770,000 | 24,233,000 |
| Total Debt | 9,492,000 | 11,147,000 | 11,436,000 |
| Cash and Cash Equivalents | 865,000 | 414,000 | 1,965,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 2,503,000 | 3,435,000 | 4,534,000 |
| Capital Expenditure | -800,000 | -790,000 | -876,000 |
| Free Cash Flow | 1,703,000 | 2,645,000 | 3,658,000 |
| Net Income | 1,592,000 | 1,846,000 | 2,892,000 |
| Net Change in Cash | -82,000 | -449,000 | 1,541,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 31,268,428.022 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 32,725,864.398 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 31,778,666.667 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 6,826,134.352 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 7,144,303.737 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 6,937,523.308 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 7,877,449.725 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 8,357,124.445 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 8,045,386.690 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 11,142,860.233 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 11,662,234.275 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 11,324,689.582 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 5.380 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 5.590 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 5.270 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 15 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: BSX demonstrates consistent revenue growth as reflected in historical income statements, with positive trends in gross profit and net income over recent periods. Strong operating cash flow and free cash flow metrics indicate operational efficiency and the ability to fund internal growth initiatives.
- Solid Market Position: Positioned within the medical devices industry and healthcare sector, BSX benefits from a stable market cap and a competitive standing, as evidenced by its performance metrics aligning with or exceeding industry averages over 1-year and 5-year periods.
- Healthy Balance Sheet: High levels of cash and cash equivalents, coupled with a manageable debt-to-equity ratio (as per balance sheet data), provide financial flexibility for strategic investments or debt servicing.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates BSX intrinsic value between $26.19 – $92.36 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about BSX valuation
Is Boston Scientific Corporation (BSX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Boston Scientific Corporation (BSX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BSX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BSX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BSX’s P/E ratio?
You can see BSX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BSX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BSX a good long-term investment?
Whether BSX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BSX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
1.32
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 61.25 | Year High: | 109.5 | |
| Price Avg 50: | 75.55 | Price Avg 200: | 94.2 | |
| Volume: | 11.552M | Average Volume: | 19.139M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeBSX full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into a comprehensive analysis of Boston Scientific Corporation, ticker BSX, a major player in the medical device industry. If you’re looking to understand whether this stock deserves a spot in your portfolio, stick around because we’re breaking down everything from financials to recent performance and even their intrinsic value. Let’s get started! So, what’s the big picture with Boston Scientific? These guys are a global leader in developing and…
